Form 4: Predictive Oncology CEO's Stock Withholding for Taxes

Predictive Oncology Inc. CEO Raymond F Vennare reported a disposition of 2,373 common shares withheld for tax purposes following the vesting of restricted stock units.

Summary

• Raymond F Vennare, Chief Executive Officer and Director of Predictive Oncology Inc. (POAI), reported a change in beneficial ownership.
• On November 28, 2025, 2,373 shares of common stock were withheld by the Issuer.
• This withholding was to cover tax obligations related to the vesting of 8,331 restricted stock units (RSUs).
• The RSUs were granted on September 9, 2025, vested in full on October 31, 2025, and were settled on November 28, 2025.
• The shares were valued at $5.9 per share for the withholding transaction.
• Following this transaction, Raymond F Vennare beneficially owns 6,418 shares of common stock directly.

Sentiment

Score: 6

Explanation: The filing reports a routine transaction related to executive compensation, specifically the vesting of restricted stock units and the subsequent withholding of shares for tax purposes. This is a standard event and does not indicate significant positive or negative operational news, hence a neutral to slightly positive sentiment due to the underlying RSU vesting.

Positives

• The vesting of 8,331 restricted stock units (RSUs) indicates the successful completion of performance or time-based conditions for the CEO's equity compensation.

Negatives

• No direct negatives for the company or investors from this routine tax withholding transaction.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it pertains to a past insider transaction.

Industry Context

This filing is specific to an individual's equity compensation and ownership changes within Predictive Oncology Inc. It does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• The settlement of restricted stock units (RSUs) and subsequent share withholding for tax purposes is a standard compensation-related transaction between the company and its Chief Executive Officer.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event. The underlying RSU grant and vesting are part of the company's established compensation plan.
• Employees: No direct impact on the broader employee base.
• Customers, Suppliers, Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 details a routine insider transaction where shares were withheld to cover tax obligations upon the vesting of restricted stock units. Such a transaction is a standard part of executive compensation and does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing does not alter the fundamental investment thesis.

Keywords

Predictive Oncology, POAI, Form 4, insider transaction, stock ownership, CEO, Raymond F Vennare, restricted stock units, RSU, equity compensation